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Abstract
Background: Neuroblastoma is the most common pediatric solid tumor. About fifty percent of high risk patients
die despite treatment making the exploration of new and more effective strategies for improving stratification
mandatory. Hypoxia is a condition of low oxygen tension occurring in poorly vascularized areas of the tumor
associated with poor prognosis. We had previously defined a robust gene expression signature measuring the
hypoxic component of neuroblastoma tumors (NB-hypo) which is a molecular risk factor. We wanted to develop a
prognostic classifier of neuroblastoma patients’ outcome blending existing knowledge on clinical and molecular
risk factors with the prognostic NB-hypo signature. Furthermore, we were interested in classifiers outputting explicit
rules that could be easily translated into the clinical setting.
Results: Shadow Clustering (SC) technique, which leads to final models called Logic Learning Machine (LLM),
exhibits a good accuracy and promises to fulfill the aims of the work. We utilized this algorithm to classify
NB-patients on the bases of the following risk factors: Age at diagnosis, INSS stage, MYCN amplification and NB-
hypo. The algorithm generated explicit classification rules in good agreement with existing clinical knowledge.
Through an iterative procedure we identified and removed from the dataset those examples which caused
instability in the rules. This workflow generated a stable classifier very accurate in predicting good and poor
outcome patients. The good performance of the classifier was validated in an independent dataset. NB-hypo was
an important component of the rules with a strength similar to that of tumor staging.
Conclusions: The novelty of our work is to identify stability, explicit rules and blending of molecular and clinical
risk factors as the key features to generate classification rules for NB patients to be conveyed to the clinic and to
be used to design new therapies. We derived, through LLM, a set of four stable rules identifying a new class of
poor outcome patients that could benefit from new therapies potentially targeting tumor hypoxia or its
consequences.
Background
Neuroblastoma is the most common solid pediatric tumor,
deriving from ganglionic lineage precursors of the sympa-
thetic nervous system [1]. It shows notable heterogeneity
of clinical behavior, ranging from rapid progression asso-
ciated with metastatic spread and poor clinical outcome to
spontaneous, or therapy-induced, regression into benign
ganglioneuroma. Age at diagnosis, stage and amplification
of the N-myc proto-oncogene (MYCN) are clinical and
molecular risk factors that the International Neuroblas-
toma Risk Group (INRG) utilized to classify patients into
high, intermediate and low risk subgroups on which cur-
rent therapeutic strategy is based. About fifty percent of
high risk patients die despite treatment making the
exploration of new and more effective strategies for
improving stratification mandatory [2].
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The availability of genomic profiles improved our
prognostic ability in many types of cancers [3]. Several
groups used gene expression-based approaches to stra-
tify neuroblastoma patients. Prognostic gene signatures
were described [4-10] and classifiers were trained to
predict the risk class and/or patients’ outcome [4-11]. It
was recently reported the design of a multi signature
ensemble classifier that merges heterogeneous, neuro-
blastoma-related gene signatures to blend their discrimi-
nating power, rather than numeric values, into a single,
highly accurate patients’ outcome predictor [12]. How-
ever, it is difficult to interpret these results with respect
to the underlying biology because the assembly of the
signature is only computational. The translation of the
computational results to the clinic requires the use of
explicit statements, coupled with the capability of blend-
ing prior knowledge on the disease with newly acquired
information from high throughput technology.
We developed a biology-driven approach which defines
the gene expression profile of a biological process known
to be relevant, by prior knowledge, to the progression of
the tumor and we then evaluate the prognostic value of
such signature. We have identified tumor hypoxia as a
feature of highly aggressive neuroblastoma [13]. Hypoxia
is a condition of low oxygen tension occurring in poorly
vascularized areas of the tumor which has profound
effects on cell growth, genotype selection, susceptibility
to apoptosis, resistance to radio- and chemotherapy,
tumor angiogenesis, epithelial to mesenchymal transition
and propagation of cancer stem cells [14-17]. Hypoxia
activates specific genes encoding angiogenic, metabolic
and metastatic factors [15,18] and contributes to the
acquisition of the tumor aggressive phenotype [15,19,20].
We have used gene expression profile to assess the
hypoxic status of neuroblastoma cells and we have
derived a robust 62-probe sets neuroblastoma hypoxia
signature (NB-hypo) [13,21] which is an independent risk
factor for neuroblastoma patients [22]. Prognostic signa-
tures that can be linked to a biological processes are of
great interest because they may redirect the choice of
drugs in the design of more effectives treatments. There-
fore, integration of the NB-hypo signature with the exist-
ing risk factors may result into an interesting, needed
and improved tool for neuroblastoma patients stratifica-
tion and treatment.
Several statistical and machine learning techniques have
been proposed in the literature to deal with output of
explicit rules and good classification performance [23].
Most available techniques, such as linear discriminant
approaches, multilayer perceptrons or support vector
machines, are able to achieve a good degree of provisional
accuracy, but construct black-box model whose function-
ing cannot allow to derive information about the pathol-
ogy of interest and its relationships with the considered
diagnostic and prognostic factors. To overcome this draw-
back, different classification methods, capable of con-
structing models described by a set of intelligible rules,
have been developed. Methods based on Boolean Function
Synthesis adopt the aggregative policy according to which
at any iteration some patterns belonging to the same out-
put class are clustered to produce an intelligible rule.
Suitable heuristic algorithms [24-26] are employed to gen-
erate rules exhibiting the highest covering and the lowest
error; a tradeoff between these two different objectives has
been obtained by applying the Shadow Clustering (SC)
technique [24] which generally leads to final models, called
Logic Learning Machines (LLM), exhibiting a good
accuracy.
In the present work, we describe the utilization of LLM
to generate rules classifying NB patients on the basis of
NB-hypo and clinical and molecular risk factors. We
found that this algorithm can generate rules stratifying
high risk neuroblastoma patients who could benefit from
new therapeutic approach related to hypoxia. Finally, we
introduce a workflow to identify the instances that gener-
ate rules instability and to generate rules with a high
degree of stability.
Results
Our aim was to derive explicit and stable rules, based on
risk factors, to stratify NB patient’s outcome. Initially, we
studied a 182 NB patients dataset characterized by three
common risk factors, Age at diagnosis, INSS stage, MYCN
oncogene amplification. “Good” or “poor” outcome classes
are defined, from here on, as the patient’s status “alive” or
“dead” 5 years after diagnosis, respectively (Table 1). The
composition of the dataset is comparable to what pre-
viously described [5]. We selected this dataset because the
gene expression profile of the primary tumor, performed
by microarray, was available for each patient. We applied
the LLM implemented by the Rulex 2.0 software to gener-
ate intelligible rules predicting patients’ outcome. The
results are shown in Table 2. The algorithm identified 5
explicit rules predicting outcome. Each rule covered more
than one patient. In fact, the total covering of patients pre-
dicted dead (rules 2.1 and 2.2) adds up to 140% but it com-
prises 96% of non overlapping poor outcome patients.
Rules 2.3, 2.4 and 2.5 include 87.1% non overlapping good
outcome patients. Classification error was calculated for
each rule as detailed in the Methods section. In general,
the prediction error was quite low with the exception of
rule 2.2 which had 13% error. This high error was some-
what predictable because the rule applies to stage 4 patients
known to be resilient to classification by common risk
factors [5]. Rule 2.5 is in total agreement with the known
good prognosis of patients diagnosed before one year of
age [27]. We then assessed the concordance of the predic-
tions with the stratification in Low (LR), Intermediate (IR)
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and High risk classes (HR) proposed by the INRG on the
same risk factors. HR patients were correctly included in
the rules classifying poor outcome patients and LR patients
mapped in the good outcome rules. The concordance
between risk prediction by the rules and previous clinical
knowledge provided the first indications of the suitability of
LLM to classify neuroblastoma patients.
Fifty one patients failed to respond to treatment and
have poor prognosis (Table 1) indicating the need to
develop and test new risk factors to improve stratification
and new therapeutic protocols. Biology-driven gene
expression signatures have the potential to fulfill the dual
purpose of generating new attributes for patients stratifica-
tion and to indicate the possible therapeutic strategy [22].
We previously described a 62-probe sets signature (NB-
hypo) that stratifies neuroblastoma patients on the bases
of outcome [22]. We addressed the effects of the addition
of NB-hypo as risk factor on outcome prediction. Rulex
utilizes only categorical attributes. We divided the patients
in groups through the application of k-means clustering of
the patients based on the 62-probe sets signature of NB-
hypo. Two was the optimal number of clusters to partition
the dataset as shown by the within cluster distance when
varying the number of clusters (see additional Figure 1 in
Additional file 1). The 182 patients were clustered in two
groups of 136 and 46 elements with Low and High NB-
hypo expression respectively (see additional Figure 2 in
Additional file 1).
Table 1 Characteristics of the neuroblastoma patients datasets
Risk factors Training seta Independent test setb
Patients Distribution (%)C Patients Distribution (%)C
Age at diagnosis (Years)
<1 86 47 26 51
≥1 96 53 25 49
INSS stage
1 42 23 13 25
2 24 13 7 14
3 23 13 11 21
4 69 38 16 32
4s 24 13 4 8
MYCN status
normal 152 84 40 79
amplified 30 16 11 21
Outcome
Good 131 72 41 80
Poor 51 28 10 20
Risk Group d
LR 94 52 27 53
IR 21 11 8 15
HR 67 37 16 32
a The total number of patients is 182. The number of patients in each subdivision is shown.
b The total number of patients is 51. The number of patients in each subdivision is shown.
c Percentage relative to the total number of patients.
d The risk assessment is based on INRG classification. HR = High Risk; IR = Intermediate Risk; LR = Low Risk.
Table 2 Classification rules predicting neuroblastoma patients’ outcome on the bases of INRG risk factors
Rule IDa INSS stage MYCN status Age at diagnosis (Years) Predicted Outcome Covering b (%) Error c (%) Risk group d
2.1 IF ( {1, 3, 4, 4s} amplified ≥1 )THEN Poor 50 1.5 HR
2.2 IF ( {4} _ ≥1 )THEN Poor 90 13 HR
2.3 IF ( {1, 2, 4s} _ <1 )THEN Good 68 1.9 LR
2.4 IF ( {1,2,3,4s} normal _ )THEN Good 81 3.9 LR
2.5 IF ( _ _ <1 )THEN Good 65 0 LR,IR
a The Rule ID is composed by the table number followed by a dot and the rule number.
b Covering is the fraction of examples in the training set that verify the rule and belong to the target class.
C Error is the fraction of examples in the training set that satisfy the rule and do not belong to the target class.
d The risk assessment is based on INRG classification taking into consideration only INSS stage, MYCN status and Age at diagnosis. HR = High Risk; IR =
Intermediate Risk; LR = Low Risk.
Cangelosi et al. BMC Bioinformatics 2013, 14(Suppl 7):S12
http://www.biomedcentral.com/1471-2105/14/S7/S12
Page 3 of 20
We tested the effect on classification of including NB-
hypo to the previously analyzed INRG risk factors and
the results are shown in Table 3. The algorithm pro-
duced a 7 rules classifier of which rules 3.1, 3.2 and 3.3
cover 76.4% of non overlapping poor outcome patients
and rules 3.4, 3.5, 3.6, and 3.7 cover 95.4% of non over-
lapping good outcome patients. We called this classifier
Initial classifier. Each rule utilizes some, but not all, con-
sidered risk factors and NB-hypo was included in three
rules demonstrating its potential in NB stratification.
The rules classifying poor outcome patients have a very
low error ranging from 1.5% to 3% indicating a good
performance of the algorithm in predicting this class.
Furthermore, rules 3.1 and 3.2 include patients with
stage 4 neuroblastoma, a group that is traditionally very
difficult to be stratified, demonstrating that NB-hypo is
an important prognostic factor for high risk patients. In
contrast, the classification of good outcome patients
produced rules with variable error, including rule 3.5
with 23% error. The statistical significance of each rule
was assessed by Fisher exact test demonstrating a high
significance of every rule with the exception of rule 3.7
that had also minimal covering. Finally, we introduced a
new parameter, the stability value, which provides an
indication of the robustness of the rules. The stability of
the rules was somewhat variable ranging from 0.50 of
rule 3.3 to 0.94 and we addressed this issue in detail
(see below). In conclusion, we demonstrated that NB-
hypo could be successfully utilized to generate rules
stratifying NB patients. Interestingly, the prognosis of
stage 4 patients took advantage of NB-hypo providing
the first evidence of the importance of this new risk fac-
tor in stratifying high risk patients.
The impact of the LLM rules on the clinic is directly
related to their stability. Our results indicated a variation
in stability that impacted on the “credibility” of the rules
and we decided to investigate further the source of varia-
bility and, possibly, to improve the reproducibility of the
rules in cross validation. Rulex 2.0 is programmed to
include every patients in at least one rule as shown in
Figure 1 thereby creating rules with very limited coverage,
like rule 3.7, and potentially highly unstable. We utilized
the stability statistical measure and the CORE procedure
to identify and eliminate the instances responsible for rule
instability according to the stabilization flowchart outlined
in Figure 2. The process consists in an iterative procedure
that removes the instances that generate instability.
The process is repeated till each rule has the maximal sta-
bility value of one. The fist iteration applied to the initial
182 patients generated seven Core rules (see additional
Table 1 in Additional file 2). Figure 3 shows the represen-
tation of the individual patients in the Core rules. The sta-
bility of the Core rules was clearly improved and four of
them reached the one value. The major change caused by
the introduction of Core rules was that 24 patients (red
dotted box) were not covered by any rule. These patients
shared the same characteristics (NB-hypo = Low, INSS
stage = 4, MYCN status = normal and Age at diagnosis ≥
1 year) but contained equal proportion of good and poor
prognosis patients. It follows that these patients are not
classifiable and their inclusion in either class depends only
on the casual imbalance in the distribution between train-
ing and test set. Another source of instability is the
rule A1.5 (blue dotted boxes) with only two patients
whose casual association with training or test set would
decide the prediction. The last case of instability regards
rule A1.2 (orange dotted box), that is almost equivalent to
rule A1.3 with the exception of one instance that is pre-
sent only in the rule A1.2. In particular, being A1.2 equiva-
lent to rule 3.2 and A1.3 equivalent to the rule 3.1, Rulex
generates a rule 3.2 only when that unique example
patient that is not covered by rule 3.1 is present in the
training set.
The above mentioned 27 patients were removed from the
dataset as source of instability and a second round of sta-
bilization (Figure 2) was started on the remaining 155
instances. The second iteration generated the second clas-
sifier having three out of five rules with a stability equal to
one (see additional Table 2 in Additional file 2) and five
Core rules in which only one had a stability smaller than
one (see additional Table 3 in Additional file 2). We iden-
tified and removed the patient that was the cause of this
instability. In the third interaction we obtained the Final
classifier consisting of four rules each with the stability of
one and lacking isolated instances (Figure 4). In conclu-
sion, we identified and removed 28 patients causing
instability corresponding to 15% of the dataset. The char-
acteristics of the Final classifier are shown in Table 4. The
statistical significance of each rule is less than 0.001 and
the error is less than 4% (0% in two rules). Rules 4.1 and
4.2 cover 100% of non overlapping poor outcome patients
and rules 4.3 and 4.4 cover 96% of non overlapping good
outcome patients. Rule 4.2 is important because it classi-
fies stage 4 tumors, and predicts poor outcome when
NB-hypo is High. Moreover, Low NB-hypo is involved in
predicting good prognosis of NB patients (Rule 4.3). We
list the INRG risk groups of the patients included in the
final rules based on age, MYCN and stage. Interestingly,
HR patients are covered by distinct rules supporting the
conclusion that NB-hypo allows the identification of new
risk groups among the NB patients. The relative relevance
of the risk factors included in the rules for the classifica-
tion was computed and the results are shown in Figure 5.
Relevance for Good outcome patients was INSS stage
0.71, NB-hypo 0.61, MYCN status 0.41, Age at diagnosis
0.0; the relevance for Poor outcome patients was INSS
0.77, NB-hypo 0.67, Age 0.24, MYCN 0.0. The relevances
of NB-hypo and INSS stage were very close but far from
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Table 3 Classification rules of neuroblastoma patients including NB-hypo
Rule IDa NB-hypo INSS Stage MYCN Status Age at diagnosis (Years) Predicted Outcome Covering b (%) ErroreC (%) Fisher pvalued Stabilitye
3.1 IF ( High {3,4} _ ≥1 ) THEN Poor 64 3 <0.001 0.94
3.2 IF ( High {2,3,4} Normal ≥1 ) THEN Poor 25 2.2 <0.001 0.8
3.3 IF ( _ {1, 3, 4, 4s} Amplified ≥1 ) THEN Poor 50 1.5 <0.001 0.5
3.4 IF ( _ _ _ <1 ) THEN Good 65 0 <0.001 0.94
3.5 IF ( Low _ Normal _ ) THEN Good 89 23 <0.001 0.64
3.6 IF ( _ {1, 4s} _ _ ) THEN Good 50 0 <0.001 0.9
3.7 IF ( _ {1, 2, 4s} Amplified _ ) THEN Good 1.5 0 >0.5 0.8
a The Rule ID is composed by the table number followed by a dot and the rule number.
b The covering is the fraction of examples in the training set that verify the rule and belong to the target class.
C The error is the fraction of examples in the training set that satisfy the rule and do not belong to the target class.
d Fisher p-value quantifies the statistical significance of the rule.


















the other risk factors providing evidence of the relevance
of NB-hypo in patients’classification.
The last task was to test the Final Classifier g(x) for
conflicts. according to the procedure indicated in the
Material and Methods Section. We identified potentially
conflicting rules in the following pairs of rules: 4.1 vs 4.3
and 4.2 vs 4.4. In fact, the pattern x having NB-hypo =
Low, INSS = 4, MYCN = normal, and Age ≥ 1 verifies
rules 4.1 and 4.3 with opposite predictions. Similarly, pat-
tern with NB-hypo = High, INSS Î {2,3}, MYCN = nor-
mal, and Age ≥ 1 satisfies the conditions rules 4.2 and
4.4, with opposite predictions. However, such instances do
not occur as it can be determine by the data in Figure 4
that demonstrate the lack of any overlapping among
patients included in the rules predicting good (Rules 4.3
and 4.4) and poor (Rules 4.1 and 4.2) outcome. There are
no patients in a conflicting situation is that because such
cases were removed by the stabilization procedure as
causes of instability. The potentially conflicting situations
could also be computed by the rules:
if NB-hypo = Low and INSS = 4 and MYCN = nor-
mal and Age ≥ 1 then NC
if NB-hypo = High and INSS Î {2,3} and MYCN =
normal and Age ≥ 1 then NC
generated as described in the Material and Methods
section. However, the use of the stabilization procedure
is superior because it identifies correctly not only 26
patients in a conflicting situation but also 2 additional
instances causing instability.
The process of stabilization of the rules is associated
with an improvement of the classification parameters.
Figure 6 shows a comparison of accuracy, recall, preci-
sion, specificity and negative predictive value among the
Initial classifier generated on the whole 182 patients data-
set, the Second classifier obtained after two cycles of
stabilization and the Final classifier. Every indicator of
the classifier performance improved concomitantly with
the strengthening of the rules’ stability with the exception
of the proportion of misclassified that decreased to null
values as expected by the nature of the stabilization
workflow (Figure 2).
10 fold cross validation is a powerful indicator of the per-
formance of our classifier in the 182 patients’ dataset.
However, the stabilization workflow called for removal of
patients from the dataset raising the question of the perfor-
mance of the algorithm on an independent dataset of neu-
roblastoma patients. We tested the predictions of the Final
classifier (Table 4) on an independent 51 patients’ dataset
(Table 1). We deleted from the 51 patients’ dataset
8 instances (15%) with the same characteristics (attribute
values) as those eliminated from the 182 dataset because
source of instability. The performance of the Final classifier
was then tested on the remaining 43 instances. The results
are shown in Table 5. The Final classifier demonstrated a
good performance on the validation set resulting in 86%
accuracy, 91% recall, 90% precision and 70% specificity and
Figure 1 Patients representation in the rules of Table 3. Plot of the membership of the 182 patients (x axis) to the rules of the classifier in
Table 3. Each patient in our dataset is covered by at least one rule.
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negative predictive value demonstrating the validity of our
approach and its reproducibility on an independent data-
set. These statistical measures of the performance are com-
parable, but somewhat lower to those obtained in cross
validation (Figure 6).
The performance of the classifier obtained considering
only MYCN, age and INSS stage without the contribu-
tion of NB-hypo (INRG risk factors) (Table 2) on the 51
patients’ dataset was then measured and the results are
shown in Table 5. Accuracy, precision, specificity were
remarkably similar. The inclusion of NB-hypo in the clas-
sifier increased somewhat recall and negative predictive
value indicating an improvement of the classification of
good outcome patients and better precision in predicting
poor outcome patients.
Finally, we compared the Final classifier with that of
the INRG consensus pretreatment classification schema
on the 51 patients’ dataset. To attempt this comparison
we had to classify the patients in risk groups using only
3 (MYCN, age and INSS stage) out of more than 16
parameters considered by INRG and to merge Low,
Very low and Intermediate risk patients into one group
to have a binary classification. The results are shown in
Table 5. Comparing the Final classifier with the INRG
Figure 2 Rules stabilization flowchart. The initial dataset is analyzed by LLM to generate the initial classifier and the stability of the rules is
assessed in cross validation as described in the Methods section. The stability of each rule is associated to the classifier which is accepted if the
stability of every rule is equal to one. If this condition does not apply, Core rules will be derived from the 50 classifiers originated by the cross
validation procedure. These rules allow to identify the instances that generate instability which are deleted from the dataset. The purged dataset
serves as input of a new cycle of analysis which is repeated till each rule has stability equal to one.
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Figure 3 Core rules representing the initial set of 182 patients. Plot of the membership of the 182 patients (x axis) to the rules of the
classifier in Additional file 2 Table 1. Red dashed box highlights the group of patients not covered by any Core Rule. Blue dashed box highlights
the only two patients covered by rule A1.5. Orange dashed box highlights the only patients that forces the existence of rule A1.2 that would be
otherwise part of A1.3.
Figure 4 Final classifier. Plot of the membership of the 154 patients remaining in the dataset after purge (x axis) to the rules of the classifier in
Table 4 (y axis). The stability of each rule is listed along the y axis.
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Table 4 Final classifier
Rule ID a NB-hypo INSS Stage MYCN Status Age at diagnosis (Years) Predicted Outcome Covering b (%) Error C
(%)
Fisher pvalued Stabiltye Risk group f
4.1 IF ( _ {4} _ ≥1 ) THEN Poor 91 4 <0.001 1 HR
4.2 IF ( High {2, 3, 4} _ ≥1 ) THEN Poor 86 3 <0.001 1 HR,IR,LR
4.3 IF ( Low _ Normal _ ) THEN Good 89 0 <0.001 1 LR,IR
4.4 IF ( _ {1 2 3 4s} Normal _ ) THEN Good 90 0 <0.001 1 LR IR
a The rule ID is composed by the table number followed by a dot and the rule number.
b Covering is the fraction of examples in the training set that verify the rule and belong to the target class.
C Error is the fraction of examples in the training set that satisfy the rule and do not belong to the target class.
d Fisher p-value quantifies the statistical significance of a rule.
e Stability is the fraction of the occurrences of a given rule in a 5 rounds of 10 folds cross validations.


















Figure 5 Importance of the risk factors present in the Final classifier. The relative relevance of the risk factors utilized by the rules utilized
by the Final classifier is shown. The risk factors are INSS stage, NB-hypo, age at diagnosis and MYCN status. Right panel shows the
determinations of Poor outcome patients and the left panel that of Good outcome patients the algorithms to generate the relevance values is
detailed in the Methods section.
Figure 6 Classification parameters and stability of the rules. The panels of figure show accuracy, recall, precision, misclassified, specificity
and negative predictive value of the initial classifier based on 182 patients (A) the second classifier based on 155 patients (B) and the Final
classifier consisting of absolutely stable rules (C).
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classification schema, we observed similar accuracy but
differences in the other classification parameters. The
Final classifier demonstrated an improvement in the
classification of good outcome patients (recall: 91% vs
83%) and a better precision in predicting poor outcome
patients (negative predictive value: 70% vs 56%), while
INRG classification schema demonstrated a better classi-
fication of poor outcome patients (specificity: 80% vs
70%) and a better precision in predicting good outcome
patients (precision: 97% vs 90% ). However, these con-
siderations provide an indication of the relationship
among these classifiers but they will have to be validated
on a larger dataset.
In conclusion, iterative application of stabilization proce-
dure generates fully stable rules that are a very powerful
tool to classify NB-patients. Figure 7 shows the workflow
of the main steps performed in our rule generation and
the references to the relevant tables and figures. The stabi-
lity of the rule is achieved at the expenses of including
every patient in the analysis, an accepted and common
practice when deciding on the rules for recruiting patients
in a clinical trials.
Discussion
We developed explicit rules, predicting the outcome of
neuroblastoma patients on the bases of Age at diagnosis,
MYCN amplification, INSS stage and NB-hypo signature.
We demonstrate that LLM algorithms generate clinically
relevant rules and that stabilization of these rules through
a novel procedure, improves the performance stratifying
high risk patients traditionally difficult to classify. Further-
more, the use of NB-hypo, a biology driven risk factor,
identifies a cohort of poor prognosis patients as potential
target of new therapeutic approaches perhaps aiming at
counteracting tissue hypoxia.
Classification is central to stratification of cancer
patients into risk groups benefiting of defined therapeutic
approaches. Several statistical and machine learning tech-
niques have been proposed to deal with this issue [23].
Each of them trains a specific model that is used to predict
the output for new unlabeled data. We privileged classifi-
cation methods capable of constructing models described
by a set of intelligible rules for their immediate translation
in the clinical setting and for the possibility to incorporate
previous medical knowledge in the algorithm. Most avail-
able techniques, such as linear discriminant approaches,
multilayer perceptrons or support vector machines, are
able to achieve a good degree of provisional accuracy, but
construct black-box model whose functioning cannot
allow to derive information about the pathology of interest
and its relationships with the considered diagnostic and
prognostic factors. Different classification methods capable
of constructing models described by a set of intelligible
rules (if< premise> then< consequence>) were developed
to overcome this drawback.
Rule generation techniques produce not only the subset
of variables actually correlated with the pathology of inter-
est, but also explicit intelligible conditions that determine
a specific diagnosis/prognosis. As a consequence, relevant
thresholds for each input variable are identified, which
represent valuable information for understanding the phe-
nomenon at hand. In general, each rule refers to a specific
target output class and it is characterized by two statistical
measures: the covering, which accounts for the fraction of
examples in the training set that verify the rule and belong
to the target class, and the error, which is given by the
portion of patterns in the training set that satisfy the rule
and do not belong to the target class. We introduced a
third statistical measure, the stability, as a prerequisite for
acceptance of a set of rules.
Table 5 Performance comparison between Final, INRG risk factors and INRG consensus pretreatment schema classifiers
Classifier Accuracy a Recall b Precision c Specificity d Negative Predictive Value e
Final f (Good vs Poor) 86% 91% 90% 70% 70%
INRG risk factors g (Good vs Poor) 82% 85% 92% 70% 53%
INRG Pretreatment Schema h (VLR/LR/IR vs HR) 84% 83% 97% 80% 56%
a Accuracy is the fraction of correctly classified patients and overall classified patients.
b Recall is the fraction of correctly classified good outcome patients and the overall predicted good outcome patients.
C Precision is the fraction of correctly classified good outcome patients and the predicted good outcome patients.
d Specificity is the fraction of correctly classified poor outcome patients and the overall poor outcome patients.
e Negative predictive value is the fraction of correctly classified poor outcome patients and the overall predicted poor outcome patients.
f Final classifier indicates the classifier in Table 4 obtained utilizing Rulex.
g INRG risk factors classifier indicates the classifier in Table 2 obtained utilizing Rulex.
h INRG Pretreatment Schema classifier indicates the INRG pretreatment classification schema.
VLR = Very Low Risk; HR = High Risk; IR = Intermediate Risk; LR = Low Risk. We computed the performance of INRG pretreatment schema classifier on the 51
patients’ cohort as follows.
We assigned Very low, Low, Intermediate, High risk utilizing the INRG consensus pretreatment classification schema considering only the Age at diagnosis, INSS
stage and MYCN status risk factors.
We then created two groups to make the risk assignment comparable with outcome.
The first included Very low, Low and Intermediate risk patients and the second included High risk patients.
The first group was associated with a favorable outcome and the second was associated with an unfavourable outcome.
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Most used rule generation techniques belong to two
broad paradigms: decision trees and methods based on
Boolean Function Synthesis. The approach adopted by
the first kind of algorithms divides iteratively the training
set into smaller subsets according to a divide and con-
quer strategy: this gives rise to a tree structure from
which an intelligible set of rules can be easily retrieved.
At each iteration a portion of the training set is split into
two or more subsets according to the results of a test on
a specific selected input variable. The target is to obtain
at the leaves of the tree structure portions of the training
set belonging to the same output class. These portions of
training set are, in general, non-overlapping [28]. Deci-
sion tree methods usually provide simple rules, which
can be directly interpreted by an expert, and require a
reduced amount of computational resources. However,
the accuracy of the developed models is often poor when
compared with that exhibited by black-box techniques.
The divide and conquer strategy leads to conditions and
rules that point out the differences among examples of
the training set belonging to different output classes. It
follows that decision tree approach implements a discri-
minant policy: differences between output classes are the
driver for the construction of the model. Several reports
emphasized the unstable characteristic of the decision
tree, quantifying the stability of a classifier or algorithm
using syntactic or semantic stability notions [29-34].
In contrast, methods based on Boolean function
synthesis adopt an aggregative policy: at any iteration
some patterns belonging to the same output class are
clustered to produce an intelligible rule. Suitable heuris-
tic algorithms [24-26] are employed to generate rules
exhibiting the highest covering and the lowest error; a
tradeoff between these two different objectives has been
Figure 7 Summing up of the rules generation. The 182 patients’ dataset was utilized to generate the initial classifier (7 rules). Following the
stabilization procedure, we identified and removed the instances causing instability in the dataset to obtain a Final classifier (4 rules). The validity
of the rules was analyzed by cross validation and by testing on an independent 51 patients’ dataset.
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obtained by applying the Shadow Clustering (SC) tech-
nique [24] which leads to final models, called Logic
Learning Machines (LLM), exhibiting a good accuracy.
The aggregative policy allows to retrieve intelligible
rules that better characterize each output class with
respect to approaches following the divide-and-conquer
strategy. Clustering examples of the same kind permit
to extract knowledge regarding similarities about the
members of a given class rather than information about
their differences. This is very useful in most applications
and leads to models showing a higher generalization
ability, as pointed out by intensive trials performed on
different datasets through SC [35,36].
LLM is an efficient implementation of the Switching
Neural Network (SNN) model [37] trained through an
optimized version of the SC algorithm. LLM, SNN and SC
have been successfully used in different applications: from
reliability evaluation of complex systems [38] to prediction
of social phenomena [39], form bulk electric assessment
[40] to analysis of biomedical data [35,36,41,42]. In parti-
cular, in this last field the ability of generating models
described by intelligible rules have carried out many
advantages, allowing to extract important knowledge from
available data. Identification of prognostic factors in tumor
diseases [41] as well as selection of relevant features
microarray experiments [35] are only two of the valuable
targets achieved through the application of LLM and
SNN. The learning approach implemented by LLM privi-
leges the covering but this is not the unique possible
approach. In the present work we privilege stability over
covering and we identify a procedure to reach this aim.
Application of LLM to NB patients dataset containing
the common risk factors MYCN, age at diagnosis, and
INSS stage, generated rules that fit with the INRG risk
assessment demonstrating the concordance of the results
of LLM with previous clinical knowledge of neuroblas-
toma. We then included NB-hypo attribute to the classifi-
cation algorithm and we demonstrated that LLM
considered this risk factor relevant for outcome prediction.
This result was important because it showed that NB-hypo
could generate clinically relevant rules identifying pre-
viously unrecognized homogeneous groups of patients.
Clinical decisions require stability of the rules because
there must be a reasonable confidence that the model is
consistent and that the predictions will be insensitive to
small changes in the dataset. For this reason we decided to
adopt suitable methods to improve the stability of the rules
even at the expenses of coverage. To this end, we devel-
oped a workflow to skim the dataset of unstable instances
maximizing the stability of each rule. The stabilization pro-
cedure is iterative and it was terminated only when each
rule has reached the maximal stability. The approach
depends on the existence of an overlap among rules and it
applies only to situations in which examples can be
covered by more than one rule. This excludes the applica-
tion of this kind of analysis to the decision tree representa-
tion that fragments the dataset into disjunctive subsets.
Iterative rules stabilization generated the Final classifier
with four rules each endowed with the maximal stability
of one. The Final classifier predicts with 3% error that
NB-Hypo High, Stage 2,3,4, older that 1 year patients
have poor outcome prediction (Table 4 Rule 4.2). Stage
2, 3, 4 patients older than 1 year are currently classified
as either low, intermediate and high INRG risk and fol-
low different therapeutic protocols. Our results indicate
that evaluation of the NB-hypo profile can lump some of
these patients into a single risk group characterized by
highly hypoxic tumors therefore, candidate for new
hypoxia targeted treatments substituting the current inef-
ficient therapies.
NB-hypo and INSS stage had similar relevance in the
generation of rules. INSS a critical parameter in neuroblas-
toma research and our data indicate that that NB-hypo is
an emerging risk factor in determining the outcome. How-
ever, neither INSS nor NB-hypo reach the relevance value
of 1 pointing to the need of multiple risk factors for
classification.
The possibility to blend previous clinical knowledge of
neuroblastoma disease with newly discovered prognostic
signatures was central to the choice of the algorithm. The
relevance of merging gene expression profiling, histo-
pathological classification was reported [12,43-47]. Several
studies deal with merging of genomic signatures, gene
expression profiles, gene mutation, genomic instability,
histopathologic and clinical classification systems in var-
ious combination for cancer classification, as exemplified
by some publications [43,46,48,49]. The characterization
of the tumor at diagnosis is indispensable for deciding the
treatment and the NB-hypo may indicate the tumors that,
as a result to the hypoxic status, express high genetic
instability [50] contain undifferentiated or cancer stem
cells [16,51] or a higher metastatic potential [17]. These
characteristics of the primary tumor may be those that
initiated the aggressiveness of the disease and could be tar-
geted by individualized treatment. Many therapeutic
agents are being developed to target hypoxia (for review
see [52]) or cells in a hypoxic environment with gene ther-
apy [53-55] and are being tested in the clinic.
The acquired stability of the rules traded off a reduced
coverage causing the exclusion of 28 out of 182 patients
from the dataset. This process is similar to that used to
design clinical protocols that is based upon selective
recruitment of a narrow group of patients with similar
expression of risk factors. There were obvious reasons to
exclude some patients from the database. Twenty four
instances shared the same attributes but were equally dis-
tributed in the two outcome classes. Under such condi-
tions the classification was entirely dependent upon the
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casual imbalance of the distribution of such patients in the
training set. Similar consideration applied to the other
patients that were excluded from the dataset to improve
the stability of the rules. We conclude that our system
generated a third class of non classifiable patients. From a
clinical perspective, there is no loss in excluding these
patients from the classification because no significant pre-
diction could be made by this or any other algorithm on
such an ambiguous cohort. In contrast, a clear gain is
achieved by strengthening the stability of the rules that
cover the remaining 85% of the patients. We identified
instances that caused instability on our dataset but we do
not exclude that others possible causes of instability could
emerge in other situations and studies are in progress to
address these issues.
Removal of the instances that caused instability was
instrumental to prevent theoretical conflicts in the classifi-
cation. Superficial inspection of the Final classifier leads to
the conclusion that there may one group of patient char-
acterized by opposite prediction. However, such instances
do not occur in the dataset after removal of the instability
cases. Therefore it is mandatory that the process of gener-
ating the rules of the Final classifier be coupled with the
stability analysis and removal of instability generating
instances. It is noteworthy that instability is not limited to
potentially conflicting instances but to other situations
including a very low covering. In this case, the casual par-
tition of such instances between training and test sets is
the true gauge for outcome prediction.
Rulex can be tuned to perform in such a way that it
associates every instance with a prediction. Under such
constrains it deals with conflicting situation by favoring
the rule that has the maximal covering among the various
possibilities. We did not feel that the covering evaluation
was a sufficient indicator to classify patients outcome. For
this reason we preferred to choose the stabilization work-
flow to identify the truly stable rules.
The performance of the Final classifier was validated in
an independent dataset to exclude the danger of overfit-
ting caused by the removal of instability instanced and
testing in cross validation in the purged dataset. The per-
formance statistical measures in the test set were quite
satisfactory demonstrating the efficacy of the classifier in
an unrelated dataset. The values were somewhat lower
than those observed in cross validation. Interestingly, the
percentage of instances generating instability were the
same in both 182 and 51 patients’ datasets. These perfor-
mance statistical measures are comparable, but somewhat
lower to those obtained in cross validation. The relatively
small number of poor outcome patients in the testing set
may account for the reduced specificity observed. A larger
testing data set would be needed to obtain a more accurate
assessment of the performance.
Conclusions
The novelty of our work is to target stability, explicit
rules and blending of risk factors as the characterizing
elements to generate classification rules for NB patients
to be conveyed to the clinic and to be used to design
new therapies.
Our first aim was to explore algorithms that could
generate intelligible classification rules of neuroblastoma
patients easily translatable into the clinical setting. We
found that LLM implemented by Rulex, was a reliable
algorithm, generating rules that paralleled the risk strati-
fication of NB patients obtained by clinical previous
knowledge.
The second major task was to develop a prognostic
classifier of NB outcome capable to blend existing clini-
cal and molecular risk factors derived from previous
clinical knowledge of the disease with the newly discov-
ered prognostic NB-hypo signature assessing the
hypoxic status of the neuroblastoma tumor. We found
that NB-hypo could be successfully associated to other
known risk factors to generate relevant prognostic rules
capable to stratify high risk patients.
We identified stability as a critical factor in the trans-
lation of the classifier into clinic and we developed a fra-
mework to maximize the stability of the rules at the
expenses of the coverage. The final product was a very
stable classifier covering 85% of the patients comprising
the original dataset. This procedure can be easily
extended to other classifiers provided that the instances
are covered by more than one rule.
From the biology standpoint we found that NB-hypo
is an important risk factor for neuroblastoma patients
that can help to resolve high risk stage 4 patients as
well as those with good prognosis. We propose that the
Final classifier derived in the present work be utilized as
bases for designing new therapies needed for the poor
prognosis patients correctly included in the NB-hypo
containing rules of our Final classifier.
Methods
Patients
The rules were established in a 182 neuroblastoma
patients’ dataset belonging to four independent cohorts
that were enrolled on the bases of the availability of
gene expression profile by Affymetrix GeneChip HG-
U133plus2.0 and clinical and molecular information.
Eighty-eight patients were collected by the Academic
Medical Center (AMC; Amsterdam, Netherlands)
[22,56]; 21 patients were collected by the University
Children’s Hospital, Essen, Germany and were treated
according to the German Neuroblastoma trials, either
NB97 or NB2004; 51 patients were collected at Hir-
oshima University Hospital or affiliated hospitals and
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were treated according to the Japanese neuroblastoma
protocols [57]; 22 patients were collected at Gaslini
Institute(Genoa, Italy) and were treated according to
Italian AIEOP or European SIOPEN protocols. The data
are stored in the R2: microarray analysis and visualiza-
tion platform [58] (AMC and Essen patients) or at the
BIT-neuroblastoma Biobank of the Gaslini Institute. The
investigators who deposited the data in the R2 reposi-
tory agree to use the data for this work. In addition, we
utilized the data present on the public database at the
Gene Expression Omnibus number GSE16237) for Hir-
oshima patients [57]. Informed consent was obtained in
accordance with institutional policies in use in each
country. In every dataset, median follow-up was longer
than 5 years and tumor stage was defined as stages 1, 2,
3, 4, or 4s according to the International Neuroblastoma
Staging System (INSS). The main features of the 182
neuroblastoma patients are listed in Table 1. Good and
poor outcome were defined as the patient’s status alive
or dead 5 years after diagnosis. The pre-treatment risk
groups of the 182 patients were assigned according to
the International Neuroblastoma Risk Group (INRG)
Consensus Pretreatment Classification schema [59]. We
utilized an independent 51 patients dataset collected at
the Gaslini Institute (Genoa, Italy) treated according to
the Italian AIEOP protocol to investigate the predictive
accuracy of the algorithm. Good and poor outcome
were defined as the patient’s status alive or dead
18 months after diagnosis.
Gene expression analysis
Gene expression profiles for the 182 tumors were obtained
by microarray experiment using Affymetrix GeneChip
HG-U133plus2.0 and the data were processed by MAS5.0
software according Affymetrix’s guideline.
Unsupervised cluster analysis
182 NB patients’ cohort was clustered by k-means analysis
of the 62 probe sets constituting the NB-hypo signature
previously described to measure tumor hypoxia [22]. The
Sum of within cluster distance was calculated to establish
the optimal partition (see Additional file 1). Analysis was
performed using 500 iterations, preserving instances order
and using Manhattan distance implemented in the WEKA
package [60].
Rules generation
In a classification problem d-dimensional examples
x ∈ d are to be assigned to one of q possible classes,
labeled by the values of a categorical output y. Starting
from a training set S including n pairs (xi,yi), i = 1,..., n,
deriving from previous observation, techniques for sol-
ving classification problems have the aim of generating a
model g(x), called classifier, that provides the correct
answer y = g(x) for most input patterns x. Concerning
the components xj two different situations can be
devised:
1 ordered variables: xj varies within an interval [a,b]
of the real axis and an ordering relationship exists
between its values.
2 nominal (categorical) variables: xj can assume only
the values contained in a finite set and there is no
ordering relationship among them.
Rule generation methods constitute a class of classifica-
tion techniques that generate intelligible models g(x)
described by a set of m rules rk, k = 1,..., m, in the if-then
form:
if < premise > then < consequence >
where <premise> is the logical product (and) of mk
conditions ckl, with l= 1,..., mk, on the components xj,
whereas <consequence> gives a class assignment y = y˜
for the output. In general, a condition ckl in the premise
involving an ordered variable xj has one of the following
forms xj >l, xj ≤ μ, l <xj ≤ μ, being l and μ two real
values, whereas a nominal variable xk leads to member-
ship conditions xk Î {a, δ, s}, being a, δ, s admissible
values for the k-th component of x.
For instance, if x1 is an ordered variable in the
domain {1,..., 100} and x2 is a nominal
component assuming values in the set {red, green,
blue}, a possible rule r1 is
if x1 > 40 and x2 ∈ {red, blue} then y = 0
where 0 denotes one of the q possible assignments
(classes).
According to the output value included in their conse-
quence part, the m rules rk describing a given model g
(x) can be subdivided into q groups G1, G2,..., Gq. Con-
sidering the training set S, any rule r Î Gl is character-
ized by four quantities: the numbers TP(r) and FP(r) of
examples (xi,yi) with yi = yl and yi ≠ yl, respectively, that
satisfy all the conditions in the premise of r, and the
numbers FN(r) and TN(r) of examples (xi,yi) with yi = yl
and yi ≠ yl, respectively, that do not satisfy at least one
of the conditions in the premise of r. Starting from TP,
FP, TN, and FN, other useful characteristic quantities,
such as the covering C(r), the error E(r), and the preci-










C(r) and P(r) are usually adopted as measures of rele-
vance for a rule r; as a matter of fact, the greater is the
covering and the precision, the higher is the generality
and the correctness of the corresponding rule.
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On the other hand, to obtain a measure of relevance R
(c) for a condition c included in the premise part of a
rule r, one can consider the rule r’ obtained by removing
that condition from
r. Since the premise part of r’ is less stringent, we
obtain that E(r’) ≥ E(r) so that the difference R(c) = E
(r’)-E(r) can be used as a measure of relevance for the
condition c of interest. Another possible choice is given
by R(c) = P(r)-P(r’), but in this case we can obtain nega-
tive values of relevance.
Since each condition c refers to a specific component
of x, it is also possible to define a measure of relevance
Rj for every input variable xj:




where the product is computed on the rules rk that
includes a condition ckl on the variable xj.
The relevance of a variable xj depends on the precision P
(rk) of the rules rk containing a condition ckl of that vari-
able and of the margin R(ckl) of the classification error in
the training set introduced by the condition ckl . Therefore,
the relevance increases with the magnitude of the preci-
sion of the rules that include the variable and with the
margin of the classification error introduced by a specific
condition. The relevance can have only values between 0
and 1 because the precision and error values range from 0
and 1 and so it is their product. The relevance can be
computed for the entire dataset and for each class. In the
latter case, only the rules predicting the expected class are
selected.
One of the rule generation methods is Logic Learning
Machine (LLM), an efficient implementation of the
Switching Neural Network (SNN) model [37] trained
through an optimized version of the Shadow Clustering
(SC) algorithm [24]. By applying LLM it is possible to
derive a set of intelligible rules possessing a generalization
ability comparable and even superior to that of best
machine learning techniques, maintaining the possibility
of understanding the mechanism involved in the classifica-
tion process.
The LLM is implemented by the Rulex software suite
[61]. The Rulex software, developed and commercialized
by Impara srl, is an integrated suite for extracting knowl-
edge from data through statistical and machine learning
techniques. An intuitive graphical interface allows to easily
apply standard and advanced algorithms for analyzing any
dataset of interest, providing the solution to classification,
regression and clustering problems.
The model g(x) generated by the LLM task of Rulex can
be utilized to produce the output class for any input pat-
tern x*. The <premise> part of each of the m intelligible
rules rk, k = 1,..., m, describing the model g(x), is checked
to determine whether it is verified by a given sample x*. If
only one rule rk is satisfied by x
*
’ then the <consequence>
part of rk will provide the class y = y
* to be assigned to x*.
In contrast, if the <premise> part of two or more rules rk
is verified by x*, Rulex will choose the class included in the
<consequence> part of the rule with the highest covering
value C(rk). Once we obtained our final classifier g(x),
including m intelligible rules rk, k = 1,..., m, we can check
whether conflicting rules are present in g(x), i.e. rules that
provide different outputs corresponding to the same pat-
tern x. Be yk the output value included in the <conse-
quence> part of the kth rule, two rules rh and rk are
conflicting if both of them are verified by a same pattern x
and yh ≠ yk.
To build classifiers we used a number of graphical
components provided by Rulex 2.0. We utilized Visuali-
zation\editing components to visualize and export the
confusion matrix, the training and validation sets, the
rules of the classifier, to access statistical data (e.g. Cov-
ering, Error and Relevance) and to edit the attributes.
We utilized a discretizer component with attribute dri-
ven incremental discretization as method for discretiza-
tion and minimum distance between different classes of
20% to pre-process the data. We utilized the Logic
Learning Machine classification component building
rules in bottom-up-mode, minimizing number of condi-
tions, allowing to exceed maximum number of condi-
tions and having maximum error allowed on the
training set of 0%. By setting upper maximum error
allowed on the training set to 0% we forced LLM to
generate rules that cover every instance of the training
set.
Stabilization procedure
To assess stability of the classifiers generated by Rulex we
developed an independent procedure called Stabilization.
The idea of the stabilization is to calculate the degree of
stability of a classifier generated by Rulex and perform a
number of suitable transformations of the dataset in such
a way that following generations of classifiers could be
more stable than the preceding one. The process stops
when a classifier generated stable results. The workflow of
the stabilization procedure is shown in Figure 2.
The procedure starts by our initial 182 patients’ dataset.
We execute LLM on the overall dataset and we generated
initial classifications rules. We then perform 5 indepen-
dent 10-fold cross validations executing LLM for each one
of the 50 iterations. We obtain 50 classifiers trained in dif-
ferent training sets and perform an analysis of stability by
calculating a stability value for each rule of the temporary
classifier. Given two classifiers g(x) and g’(x) generated in
two distinct iterations of n independent m-fold cross vali-
dations, we say that rk and rh are occurrences of the same
rule r if and only if for some distance metric d, d(rk, r,)<ε
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and d(r, rh)<ε for some arbitrary value ε. From the occur-
rences we define a new statistical measure called stability
as follows. Given a classifier g(x), a rule rk Î g(x) and a
number n+m of classifiers obtained by n independent m-
fold cross validations, we say that Stability(rk) = b/(n+m)
for some 0 ≤ b ≤ n+m if and only if exist b occurrences of
rk in the n+m classifiers. Given a classifier g(x), we say that
g(x) is a stable classifier if and only if for each rule rk Î g
(x) we have (1-ν) ≤ Stability(rk) ≤ 1 for some ν <1 arbitra-
rily selected. The maximum stability of a rule is when
Stability(rk) = 1. We compute the stability for every classi-
fication rule. If each of them is stable we stop the stabiliza-
tion procedure, and the classification rules become the
Final classifier. If even one rule is not stable, we identify
the instances in the initial dataset that are the causes of
the instability. To this end we introduce the notion of
Core rules. Given two classifiers g(x) and g’(x) and two
rules rk =(xi,yi) Î g(x) and rh =(xj,yi) Î g’(x), we define a
Core rule r a rule of the form r = (xi ∩ xj, yi). Core rule is a
rule obtained by intersecting the conditions of two or
more rules generated by distinct classifiers. A Core rule
gives information about what instances remained con-
served through cross validations and we use it to identify
instances that do not preserve through cross validations.
We developed a procedure, named “CORE procedure”
to identify the Core rules. Given sets of rules generated
in a number n+m iterations of cross validations, the
CORE procedure performs the following steps. First, it
identifies similar rules from the n+m classifiers. Second,
it generates a Core rule from these rules. Third, it calcu-
lates the stability statistical measure of the Core rule
from the stability statistical measures of the component
rules. Fourth, it returns the Core rule set and the stabi-
lity values.
We utilize the information given by the stability statis-
tical measure and the Core rules to identify the cause of
instability among the instances of the dataset. A number
of situations can generate instability in the rules of a
classifier generated with LLM. We identified three
major specific causes of instability. The first regards
instances covered by a given rule rk for which Stability
(rk)<1-ν and Covering(rk)≤ s for some real number s<1.
In this case, if s is small (e.g. s = 0.1 ) LLM could gener-
ate a rule that covers the instances only when all of
them are in the training set, but LLM will not generate
that rule when one or some them is in the validation
set. To introduce the second cause of instability we
need to extend our notation. Given a rules rk Î g(x) we
introduce the set H(rk) of the instances of the training
set that are covered by rk.. Given two rules rk , rh Î g(x)
such that H(rk) \ H(rh) = H(r’) where | H(r’) |<s for
some small natural number s≥ 1 (e.g. s = 1), the
instances in H(r’) can be the second cause of instability.
In this case, LLM generates both rules in the same clas-
sifier only when the instances in H(r’) are in the training
set. The third cause of instability could occur when in
the dataset there is a group of instances with the same
premises but different consequences (i.e. same premise
but half of them has a class value different from the
other half). In this case, LLM generates different rule set
if in the training set there is a larger number of
instances of one class or of another. The instances iden-
tified as cause of instability are then removed from the
dataset and the purged new dataset is used as new input
dataset.
Statistical analysis
To test the statistical significance of the rules we used a
Fisher’s Exact test (FET) implemented by the software
package R. Given a rule r:(X,y), FET calculates the exact
probability of observing the particular arrangement of
the number of instances satisfying × and y, × and ¬y,
¬X and y and ¬X and ¬y assuming the marginal total y
and ¬y under the null hypothesis that X and ¬X are
equally probable to have y as consequent. We define y
as good outcome patients and ¬y as poor outcome
when we considers rules classifying good outcome.
We switch y with ¬y for the rules classifying poor out-
come patients.
To test the predictions of the classifiers we use the
following metrics: accuracy, recall, specificity, negative
predictive values (NPV) and we considered good out-
come patients as positive instances and poor outcome
patients as negative instances. Accuracy is the propor-
tion of correctly predicted in the overall number of
instances. Recall is the proportion of correctly positive
predicted against all positive of the dataset. Precision is
the proportion of the positives correctly classified
against all the predicted positive. Specificity is the pro-
portion of correctly negative predicted against all the
negative of the dataset. NPV is the proportion of the
negative correctly classified against all the predicted
negative.
To summarize and display the distribution of the per-
formance we utilized boxplot diagrams. Boxplot shows a
box that contains the 50% of the dataset. The upper
edge of the box indicates the 3rd quantile while the
lower indicates the 1st quantile. The range in the middle
between 1st-3rd quantile is known as inter-quantile
range (IQR). The line within the box indicates the med-
ian (2nd quantile). The ends of the vertical whiskers
indicate the minimum and the maximum value of the
dataset and when outliers are present in the dataset the
whiskers extend until a maximum of 1.5 times the IQR
area. Any value outside these points is considered as a
potential outlier and is represented with a circle.
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Additional material
Additional file 1: Patients’ clustering according to the NB-hypo
signature. the file contains two figures relative to the k-mean clustering
of the 182 patients into groups differing for the expression of the
62-probe sets NB-hypo signature. Additional file 1. Figure 1. Number of
clusters selection. NB-hypo 62 probe sets gene expression data of the 182
patients cohort were clustered using k-means algorithm and the Sum of
within cluster distance was calculated. The figure shows the plot of the
Sum of within cluster distance varying the initial number of clusters. The
curve is basically flat after two clusters showing that the dichotomization
of the dataset is preferable and that no major gain can be achieved
dividing the dataset further. Additional file 1. Figure 2. Heatmap of
clustered 62 probe sets of the NB-hypo signature The expression data for
each probe set were scaled and represented by pseudo-colors in the
heatmap. Red color corresponds to high level of expression and green
color corresponds to low level of expression. These data confirm
previous findings on a smaller number of patients [22] that k-means
clustering dichotomized High and Low NB-hypo expressing tumors.
Additional file 2: Classifiers generated by the stabilization
procedure. Description of data: the stabilization procedure is described
in the Methods section and summarized in Figure 2. The procedure calls
for an iterative approach and the intermediate results are collected in
the three tables of Additional file 2. Additional file 2. Table 1Core rules
from the first iteration of the stabilization procedure. The Core rules
generated by the first iteration of the stabilization procedure are shown
together with prediction outcome and stability of each rule. Additional
file 2. Table 2. Classification rules of the second iteration on a purged 155
patients’ dataset. The dataset is reduced because the instances causing
instability were removed in the first iteration. The classification rules
generated by the second iteration of the stabilization procedure are
shown together with prediction outcome and stability of each rule.
Additional file 2. Table 3Core rules from the second iteration of the
stabilization procedure. The Core rules generated by the second iteration
of the stabilization procedure are shown together with prediction
outcome and stability of each rule.
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